XTLB logo

XTL Biopharmaceuticals (XTLB) EBITDA

Annual EBITDA

-$765.00 K
+$114.00 K+12.97%

December 31, 2023

Summary

Performance

1-Year Change

+12.97%

3-Year Change

+19.22%

5-Year Change

+3.53%

15-Year Change

+38.6%

XTLB EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

78.16%
XTLB annual EBITDA is higher than 78.16% of companies in Healthcare sector

High & Low

All-time High

$2.59 M
XTLB annual EBITDA is currently -129.57% below its historical high of $2.59 million

3-Year Low

-$1.03 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
XTLB previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Apr 30, 2025
XTLB next annual earnings announcement is scheduled for Apr 30, 2025

OtherXTLBprofitabilitymetrics:

Annual Revenue

-
XTLB annual revenue value is unknown

Annual Net Income

-$1.78 M
XTLB annual net profit is -$1.78 million

Annual EBIT

-$765.00 K
XTLB annual earnings before interest & taxes is -$765.00 thousand

Annual EPS

-$0.30
XTLB annual earnings per share is -$0.30

Quarterly EBITDA

-$460.00 K
+$231.00 K+33.43%

September 30, 2024

Summary

Performance

3-Month Change

+33.43%

1-Year Change

-191.82%

3-Year Change

-191.82%

5-Year Change

-212.2%

XTLB Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

72.49%
XTLB quarterly EBITDA is higher than 72.49% of companies in Healthcare sector

High & Low

All-time High

$5.16 M
XTLB quarterly EBITDA is currently -108.91% below its historical high of $5.16 million

3-Year Low

-$894.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
XTLB previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 30, 2025
XTLB next earnings announcement is scheduled for Apr 30, 2025

OtherXTLBprofitabilitymetrics:

Quarterly Revenue

$162.00 K
XTLB quarterly revenue is $162.00 thousand

Quarterly Net Income

-$553.00 K
XTLB quarterly net profit is -$553.00 thousand

Quarterly EBIT

-$460.00 K
XTLB quarterly earnings before interest & taxes is -$460.00 thousand

Quarterly EPS

-$0.16
XTLB quarterly earnings per share is -$0.16

TTM EBITDA

-$2000.00
-$273.00 K-100.74%

September 30, 2024

Summary

Performance

3-Month Change

-100.74%

1-Year Change

-100.32%

3-Year Change

-100.32%

5-Year Change

+99.8%

XTLB TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

76.34%
XTLB TTM EBITDA is higher than 76.34% of companies in Healthcare sector

High & Low

All-time High

$5.34 M
XTLB TTM EBITDA is currently -100.04% below its historical high of $5.34 million

3-Year Low

-$2.35 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
XTLB previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 30, 2025
XTLB next earnings announcement is scheduled for Apr 30, 2025

OtherXTLBprofitabilitymetrics:

TTM Revenue

$162.00 K
XTLB TTM revenue is $162.00 thousand

TTM Net Income

-$1.06 M
XTLB TTM net profit is -$1.06 million

TTM EBIT

-$2000.00
XTLB TTM earnings before interest & taxes is -$2000.00

TTM EPS

-$0.20
XTLB TTM earnings per share is -$0.20

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$765.00 K
XTLB annual EBITDA is -$765.00 thousand

Annual Net Income

-$1.78 M
XTLB annual net profit is -$1.78 million

Annual Interest Expense

-
XTLB annual interest expense value is unknown

Annual Income Tax

-
XTLB annual income tax value is unknown

Annual D&A

$0.00
XTLB annual depreciation & amortization is $0.00

XTLB EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+13.0%-191.8%-100.3%
3 y3 years+19.2%-191.8%-100.3%
5 y5 years+3.5%-212.2%+99.8%

XTLB EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+25.7%-171.0%+48.5%-100.3%+99.9%
5 y5-yearat high+25.7%-171.0%+59.8%-100.3%+99.9%
alltimeall time-129.6%+97.0%-108.9%+98.3%-100.0%+100.0%

XTL Biopharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$460.00 K(-33.4%)
-$2000.00(-100.7%)
Jun 2024
-
-$691.00 K(-237.9%)
$271.00 K(-57.0%)
Mar 2024
-
$501.00 K(-22.7%)
$630.00 K(-182.4%)
Dec 2023
-$765.00 K(-13.0%)
$648.00 K(-446.5%)
-$765.00 K(-55.4%)
Sep 2023
-
-$187.00 K(-43.7%)
-$1.72 M(-26.9%)
Jun 2023
-
-$332.00 K(-62.9%)
-$2.35 M(+2.5%)
Mar 2023
-
-$894.00 K(+196.0%)
-$2.29 M(+160.1%)
Dec 2022
-$879.00 K(-14.7%)
-$302.00 K(-63.1%)
-$880.00 K(+1.9%)
Sep 2022
-
-$819.00 K(+198.9%)
-$864.00 K(-1516.4%)
Jun 2022
-
-$274.00 K(-153.2%)
$61.00 K(-107.5%)
Mar 2022
-
$515.00 K(-280.1%)
-$809.00 K(-48.0%)
Dec 2021
-$1.03 M(+8.8%)
-$286.00 K(-369.8%)
-$1.56 M(+1.9%)
Sep 2021
-
$106.00 K(-109.3%)
-$1.53 M(+24.9%)
Jun 2021
-
-$1.14 M(+393.1%)
-$1.22 M(+22.1%)
Mar 2021
-
-$232.00 K(-9.7%)
-$1.00 M(-2.4%)
Dec 2020
-$947.00 K(+12.5%)
-$257.00 K(-162.7%)
-$1.03 M(+1.3%)
Sep 2020
-
$410.00 K(-144.4%)
-$1.01 M(-37.5%)
Jun 2020
-
-$923.00 K(+259.1%)
-$1.62 M(+80.3%)
Mar 2020
-
-$257.00 K(+5.3%)
-$900.00 K(+6.9%)
Dec 2019
-$842.00 K(+6.2%)
-$244.00 K(+22.6%)
-$842.00 K(+2.8%)
Sep 2019
-
-$199.00 K(-0.5%)
-$819.00 K(+1.1%)
Jun 2019
-
-$200.00 K(+0.5%)
-$810.00 K(-56.8%)
Mar 2019
-
-$199.00 K(-10.0%)
-$1.87 M(+136.2%)
Dec 2018
-$793.00 K(-36.4%)
-$221.00 K(+16.3%)
-$793.00 K(-43.0%)
Sep 2018
-
-$190.00 K(-85.0%)
-$1.39 M(+57.8%)
Jun 2018
-
-$1.26 M(-243.4%)
-$882.00 K(+1503.6%)
Mar 2018
-
$881.00 K(-207.4%)
-$55.00 K(-95.6%)
Dec 2017
-$1.25 M(-27.3%)
-$820.00 K(-356.3%)
-$1.25 M(+54.8%)
Sep 2017
-
$320.00 K(-173.4%)
-$805.00 K(-42.9%)
Jun 2017
-
-$436.00 K(+40.6%)
-$1.41 M(-2.0%)
Mar 2017
-
-$310.00 K(-18.2%)
-$1.44 M(-15.6%)
Dec 2016
-$1.71 M(-14.3%)
-$379.00 K(+33.0%)
-$1.70 M(-19.1%)
Sep 2016
-
-$285.00 K(-38.7%)
-$2.11 M(-4.5%)
Jun 2016
-
-$465.00 K(-19.1%)
-$2.21 M(-0.6%)
Mar 2016
-
-$575.00 K(-26.4%)
-$2.22 M(+10.1%)
Dec 2015
-$2.00 M(+1.6%)
-$781.00 K(+102.9%)
-$2.02 M(+6.2%)
Sep 2015
-
-$385.00 K(-19.6%)
-$1.90 M(+1.6%)
Jun 2015
-
-$479.00 K(+29.1%)
-$1.87 M(+6.1%)
Mar 2015
-
-$371.00 K(-44.0%)
-$1.76 M(-10.2%)
Dec 2014
-$1.97 M(+79.3%)
-$663.00 K(+86.2%)
-$1.96 M(+161.0%)
Sep 2014
-
-$356.00 K(-4.3%)
-$752.00 K(-661.2%)
Jun 2014
-
-$372.00 K(-35.0%)
$134.00 K(-120.4%)
Mar 2014
-
-$572.00 K(-204.4%)
-$656.00 K(-40.3%)
DateAnnualQuarterlyTTM
Dec 2013
-$1.10 M(-54.1%)
$548.00 K(+3.4%)
-$1.10 M(-62.6%)
Sep 2013
-
$530.00 K(-145.6%)
-$2.94 M(-17.6%)
Jun 2013
-
-$1.16 M(+14.6%)
-$3.57 M(+18.1%)
Mar 2013
-
-$1.01 M(-21.6%)
-$3.02 M(+27.3%)
Dec 2012
-$2.39 M(+112.1%)
-$1.29 M(+1233.0%)
-$2.37 M(+69.9%)
Sep 2012
-
-$97.00 K(-84.3%)
-$1.40 M(-10.7%)
Jun 2012
-
-$616.00 K(+67.8%)
-$1.56 M(+29.8%)
Mar 2012
-
-$367.00 K(+15.8%)
-$1.21 M(+5.1%)
Dec 2011
-$1.13 M(-9.8%)
-$317.00 K(+20.1%)
-$1.15 M(+1.3%)
Sep 2011
-
-$264.00 K(+2.7%)
-$1.13 M(-1.9%)
Jun 2011
-
-$257.00 K(-16.8%)
-$1.15 M(-4.7%)
Mar 2011
-
-$309.00 K(+2.3%)
-$1.21 M(-1.9%)
Dec 2010
-$1.25 M(-148.3%)
-$302.00 K(+5.6%)
-$1.23 M(-129.2%)
Sep 2010
-
-$286.00 K(-8.9%)
$4.23 M(-0.4%)
Jun 2010
-
-$314.00 K(-5.4%)
$4.24 M(+26.7%)
Mar 2010
-
-$332.00 K(-106.4%)
$3.35 M(-37.3%)
Dec 2009
$2.59 M(-114.1%)
$5.16 M(-2004.1%)
$5.34 M(-164.5%)
Sep 2009
-
-$271.00 K(-77.6%)
-$8.28 M(-10.1%)
Jun 2009
-
-$1.21 M(-172.7%)
-$9.21 M(-20.8%)
Mar 2009
-
$1.66 M(-119.7%)
-$11.63 M(+2.7%)
Dec 2008
-$18.40 M(-28.2%)
-$8.46 M(+605.3%)
-$11.32 M(-61.6%)
Sep 2008
-
-$1.20 M(-66.9%)
-$29.50 M(+5.1%)
Jun 2008
-
-$3.63 M(-284.3%)
-$28.08 M(-12.4%)
Mar 2008
-
$1.97 M(-107.4%)
-$32.05 M(-5.5%)
Dec 2007
-$25.63 M(+62.2%)
-$26.64 M(<-9900.0%)
-$33.91 M(+43.4%)
Sep 2007
-
$226.00 K(-103.0%)
-$23.65 M(-0.5%)
Jun 2007
-
-$7.61 M(-6772.8%)
-$23.77 M(+19.3%)
Mar 2007
-
$114.00 K(-100.7%)
-$19.91 M(0.0%)
Dec 2006
-$15.80 M(+27.9%)
-$16.39 M(<-9900.0%)
-$19.91 M(+4.7%)
Sep 2006
-
$114.00 K(-103.0%)
-$19.03 M(+1.0%)
Jun 2006
-
-$3.75 M(-3393.0%)
-$18.84 M(+6.9%)
Mar 2006
-
$114.00 K(-100.7%)
-$17.63 M(+7.2%)
Dec 2005
-$12.36 M(-24.9%)
-$15.50 M(-5354.2%)
-$16.44 M(-19.0%)
Sep 2005
-
$295.00 K(-111.6%)
-$20.31 M(+2.9%)
Jun 2005
-
-$2.54 M(-294.8%)
-$19.74 M(-11.3%)
Mar 2005
-
$1.30 M(-106.7%)
-$22.25 M(-1.9%)
Dec 2004
-$16.46 M(+16.5%)
-$19.37 M(-2341.7%)
-$22.69 M(+582.3%)
Sep 2004
-
$864.00 K(-117.1%)
-$3.33 M(-20.6%)
Jun 2004
-
-$5.05 M(-685.0%)
-$4.19 M(-585.0%)
Mar 2004
-
$864.00 K
$864.00 K
Dec 2003
-$14.12 M(-20.3%)
-
-
Dec 2002
-$17.71 M(+17.1%)
-
-
Dec 2001
-$15.12 M
-
-

FAQ

  • What is XTL Biopharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for XTL Biopharmaceuticals?
  • What is XTL Biopharmaceuticals annual EBITDA year-on-year change?
  • What is XTL Biopharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for XTL Biopharmaceuticals?
  • What is XTL Biopharmaceuticals quarterly EBITDA year-on-year change?
  • What is XTL Biopharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for XTL Biopharmaceuticals?
  • What is XTL Biopharmaceuticals TTM EBITDA year-on-year change?

What is XTL Biopharmaceuticals annual EBITDA?

The current annual EBITDA of XTLB is -$765.00 K

What is the all time high annual EBITDA for XTL Biopharmaceuticals?

XTL Biopharmaceuticals all-time high annual EBITDA is $2.59 M

What is XTL Biopharmaceuticals annual EBITDA year-on-year change?

Over the past year, XTLB annual EBITDA has changed by +$114.00 K (+12.97%)

What is XTL Biopharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of XTLB is -$460.00 K

What is the all time high quarterly EBITDA for XTL Biopharmaceuticals?

XTL Biopharmaceuticals all-time high quarterly EBITDA is $5.16 M

What is XTL Biopharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, XTLB quarterly EBITDA has changed by -$961.00 K (-191.82%)

What is XTL Biopharmaceuticals TTM EBITDA?

The current TTM EBITDA of XTLB is -$2000.00

What is the all time high TTM EBITDA for XTL Biopharmaceuticals?

XTL Biopharmaceuticals all-time high TTM EBITDA is $5.34 M

What is XTL Biopharmaceuticals TTM EBITDA year-on-year change?

Over the past year, XTLB TTM EBITDA has changed by -$632.00 K (-100.32%)